Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.31
HSP's Cash to Debt is ranked higher than
54% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. HSP: 0.31 )
HSP' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.31

Equity to Asset 0.52
HSP's Equity to Asset is ranked higher than
62% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. HSP: 0.52 )
HSP' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.65
Current: 0.52

0.28
0.65
Interest Coverage 0.19
HSP's Interest Coverage is ranked lower than
54% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.76 vs. HSP: 0.19 )
HSP' s 10-Year Interest Coverage Range
Min: 0.19   Max: 9999.99
Current: 0.19

0.19
9999.99
F-Score: 7
Z-Score: 3.72
M-Score: -2.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.85
HSP's Operating margin (%) is ranked higher than
77% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. HSP: 10.85 )
HSP' s 10-Year Operating margin (%) Range
Min: 0.41   Max: 16.17
Current: 10.85

0.41
16.17
Net-margin (%) 7.48
HSP's Net-margin (%) is ranked higher than
76% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. HSP: 7.48 )
HSP' s 10-Year Net-margin (%) Range
Min: -0.23   Max: 11.4
Current: 7.48

-0.23
11.4
ROE (%) 10.63
HSP's ROE (%) is ranked higher than
82% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. HSP: 10.63 )
HSP' s 10-Year ROE (%) Range
Min: -0.31   Max: 24.74
Current: 10.63

-0.31
24.74
ROA (%) 5.29
HSP's ROA (%) is ranked higher than
79% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. HSP: 5.29 )
HSP' s 10-Year ROA (%) Range
Min: -0.16   Max: 13.13
Current: 5.29

-0.16
13.13
ROC (Joel Greenblatt) (%) 17.81
HSP's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. HSP: 17.81 )
HSP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 0.67   Max: 53.84
Current: 17.81

0.67
53.84
Revenue Growth (3Y)(%) 1.50
HSP's Revenue Growth (3Y)(%) is ranked higher than
66% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. HSP: 1.50 )
HSP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.9   Max: 12.4
Current: 1.5

-0.9
12.4
EBITDA Growth (3Y)(%) -32.30
HSP's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.30 vs. HSP: -32.30 )
HSP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -32.3   Max: 15.4
Current: -32.3

-32.3
15.4
» HSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

HSP Guru Trades in Q4 2013

Steven Cohen 38,505 sh (New)
Paul Tudor Jones 14,676 sh (New)
Jim Simons 39,500 sh (New)
Mario Gabelli 117,670 sh (+11.15%)
John Rogers 4,670,630 sh (+5.28%)
Michael Price 400,000 sh (unchged)
Brian Rogers 2,500,000 sh (unchged)
Robert Bruce 10,000 sh (unchged)
Vanguard Health Care Fund 6,826,070 sh (unchged)
Larry Robbins Sold Out
Pioneer Investments Sold Out
Richard Snow 804,722 sh (-0.85%)
Jeff Auxier 218,080 sh (-6.38%)
» More
Q1 2014

HSP Guru Trades in Q1 2014

Jim Simons 151,800 sh (+284.3%)
Mario Gabelli 153,770 sh (+30.68%)
Vanguard Health Care Fund 8,375,170 sh (+22.69%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Richard Snow Sold Out
Brian Rogers Sold Out
Jeff Auxier 205,530 sh (-5.75%)
John Rogers 4,127,850 sh (-11.62%)
Paul Tudor Jones 10,800 sh (-26.41%)
Steven Cohen 17,130 sh (-55.51%)
» More
Q2 2014

HSP Guru Trades in Q2 2014

Mario Gabelli 204,370 sh (+32.91%)
Jim Simons 182,900 sh (+20.49%)
Michael Price 400,000 sh (unchged)
Vanguard Health Care Fund 8,375,170 sh (unchged)
Robert Bruce 10,000 sh (unchged)
Jeff Auxier 181,463 sh (-11.71%)
John Rogers 3,130,809 sh (-24.15%)
Paul Tudor Jones 7,700 sh (-28.7%)
» More
Q3 2014

HSP Guru Trades in Q3 2014

Joel Greenblatt 313,242 sh (New)
Paul Tudor Jones 24,894 sh (+223.3%)
Jim Simons 323,100 sh (+76.65%)
Mario Gabelli 254,870 sh (+24.71%)
Michael Price 400,000 sh (unchged)
Vanguard Health Care Fund 8,375,170 sh (unchged)
Robert Bruce 10,000 sh (unchged)
John Rogers 2,433,369 sh (-22.28%)
Jeff Auxier 127,307 sh (-29.84%)
» More
» Details

Insider Trades

Latest Guru Trades with HSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Rogers 2014-09-30 Reduce -22.28%0.45%$49.59 - $56.21 $ 62.6618%2433369
Joel Greenblatt 2014-09-30 New Buy0.16%$49.59 - $56.21 $ 62.6618%313242
Mario Gabelli 2014-09-30 Add 24.71%0.01%$49.59 - $56.21 $ 62.6618%254870
John Rogers 2014-06-30 Reduce -24.15%0.53%$42.14 - $52.41 $ 62.6632%3130809
Mario Gabelli 2014-06-30 Add 32.91%0.01%$42.14 - $52.41 $ 62.6632%204370
Richard Snow 2014-03-31 Sold Out 1.3%$40.89 - $45 $ 62.6646%0
Brian Rogers 2014-03-31 Sold Out 0.37%$40.89 - $45 $ 62.6646%0
John Rogers 2014-03-31 Reduce -11.62%0.28%$40.89 - $45 $ 62.6646%4127850
Vanguard Health Care Fund 2014-03-31 Add 22.69%0.18%$40.89 - $45 $ 62.6646%8375170
Mario Gabelli 2014-03-31 Add 30.68%0.01%$40.89 - $45 $ 62.6646%153770
John Rogers 2013-12-31 Add 5.28%0.12%$38.53 - $42.19 $ 62.6656%4670630
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Hospira Inc

John Rogers Comments on Hospira Inc. - Jul 25, 2013

Injectible drug specialist Hospira, Inc. (HSP) shot up +16.69% on good and surprising news about a new compound. Specifically, its Inflectra drug—a biosimilar medicine to Remicade— was recommended for approval by a crucial European authority for multiple treatments. In Europe, it is likely to be approved to treat rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. Typically, a drug is only approved for one condition first and then may receive other indications over time. Given Remicade had sales of roughly $2 billion in Europe last year, this was huge news. In recent quarters, there has been such a tight focus on existing facilities and historical problems that few have looked to the future. Our point of view has been the issues will get fixed and the company will go on to create new and better compounds to continue to drive growth; it seems the market needed a reminder such a future was even possible.

From John RogersAriel Fund Second Quarter 2013 Commentary.


Check out John Rogers latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 32.30
HSP's P/E(ttm) is ranked higher than
81% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.60 vs. HSP: 32.30 )
HSP' s 10-Year P/E(ttm) Range
Min: 8.48   Max: 133.97
Current: 32.3

8.48
133.97
P/B 3.16
HSP's P/B is ranked higher than
74% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. HSP: 3.16 )
HSP' s 10-Year P/B Range
Min: 1.52   Max: 5.83
Current: 3.16

1.52
5.83
P/S 2.40
HSP's P/S is ranked higher than
81% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. HSP: 2.40 )
HSP' s 10-Year P/S Range
Min: 0.99   Max: 2.89
Current: 2.4

0.99
2.89
PFCF 63.29
HSP's PFCF is ranked higher than
83% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. HSP: 63.29 )
HSP' s 10-Year PFCF Range
Min: 8.32   Max: 203.78
Current: 63.29

8.32
203.78
EV-to-EBIT 24.64
HSP's EV-to-EBIT is ranked higher than
82% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. HSP: 24.64 )
HSP' s 10-Year EV-to-EBIT Range
Min: -1403.5   Max: 508.2
Current: 24.64

-1403.5
508.2
Shiller P/E 49.62
HSP's Shiller P/E is ranked higher than
82% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.36 vs. HSP: 49.62 )
HSP' s 10-Year Shiller P/E Range
Min: 12.55   Max: 49.73
Current: 49.62

12.55
49.73
Current Ratio 2.36
HSP's Current Ratio is ranked higher than
71% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. HSP: 2.36 )
HSP' s 10-Year Current Ratio Range
Min: 1.61   Max: 3.03
Current: 2.36

1.61
3.03
Quick Ratio 1.34
HSP's Quick Ratio is ranked higher than
64% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. HSP: 1.34 )
HSP' s 10-Year Quick Ratio Range
Min: 1   Max: 2.04
Current: 1.34

1
2.04

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.01
HSP's Price/Tangible Book is ranked higher than
72% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.32 vs. HSP: 5.01 )
HSP' s 10-Year Price/Tangible Book Range
Min: 3.04   Max: 76.38
Current: 5.01

3.04
76.38
Price/DCF (Projected) 2.23
HSP's Price/DCF (Projected) is ranked higher than
87% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. HSP: 2.23 )
HSP' s 10-Year Price/DCF (Projected) Range
Min: 0.91   Max: 1.88
Current: 2.23

0.91
1.88
Price/Median PS Value 1.24
HSP's Price/Median PS Value is ranked higher than
74% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. HSP: 1.24 )
HSP' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 1.37
Current: 1.24

0.62
1.37
Price/Graham Number 2.67
HSP's Price/Graham Number is ranked higher than
82% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.17 vs. HSP: 2.67 )
HSP' s 10-Year Price/Graham Number Range
Min: 1.85   Max: 9.99
Current: 2.67

1.85
9.99
Earnings Yield (Greenblatt) 4.10
HSP's Earnings Yield (Greenblatt) is ranked higher than
82% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. HSP: 4.10 )
HSP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 10
Current: 4.1

0.2
10
Forward Rate of Return (Yacktman) -3.86
HSP's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.85 vs. HSP: -3.86 )
HSP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.6   Max: 18.4
Current: -3.86

-1.6
18.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HOS.Germany,
Hospira, Inc. was incorporated in Delaware on September 16, 2003. The Company is a provider of injectable drugs and infusion technologies. Its portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company conducts operations and is managed in three reportable segments: Americas; Europe, Middle East and Africa; and Asia Pacific. The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa; and the APAC segment includes Asia, Japan, Australia and New Zealand. The Company offers Specialty injectable pharmaceutical, Medication management & other pharmaceuticals. The Company's specialty injectable pharmaceutical product category mainly consists of generic injectable pharmaceuticals. These products provide customers with a lower-cost alternative to branded products, when the patent protection has expired, when patents have been declared invalid, or when the products do not infringe the patents of others. These drugs' therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other areas. The Company's other pharmaceuticals mainly consist of large volume I.V. solution, nutritional and contract manufacturing services. The Company offers infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for the washing and cleansing of wounds or surgical sites. Its contract manufacturing services are offered through its One2One(SM) services group. The Company's medication management products include electronic drug delivery pumps, safety software and disposable administration sets dedicated to the company's pumps. These sets are used to deliver I.V. fluids and medications. Medication management includes TheraDoc, Inc. products, which are module-based clinical surveillance systems that provide patient safety surveillance and clinical decision support. Medication management also includes gravity administration sets and other device products, including needlestick safety products and programs to support Hospira's customers. The Company's main customers in the Americas segment include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its main customers in the EMEA and APAC segments are hospitals and wholesalers that serve through its own sales force and its distributors. In the U.S., the Company's products are mainly distributed through a network of Company-operated distribution facilities and third-party logistics providers. The Company's competitors in specialty injectable pharmaceuticals in the Americas segment include Baxter International Inc., Bedford Laboratories, Fresenius Kabi, Pfizer, Sandoz
» More Articles for HSP

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
Brian Rogers' T. Rowe Price Equity Income Fund Semi-Annual Report 2013 Dec 02 2013 
Ariel Capital's John Rogers Trims Sotheby’s, DeVry, Hospira, IPG, Others Nov 18 2013 
Five Companies Cut - Pzena Investment Management Update Nov 12 2013 
John Rogers Comments on Hospira Inc. Jul 25 2013 
Rowe Price Equity Income Fund Buys Apple, Carnival, Joy Global, Sells Thermo Fisher, Energizer, SLM Jul 19 2013 
John Rogers Ariel Fund Second Quarterly Commentary Jul 18 2013 
Brian Rogers' Top 3 Increases and Decreases of Q2 Jul 17 2013 

More From Other Websites
Hospira to Present at the J.P. Morgan 33rd Annual Healthcare Conference Jan. 14, 2015 Dec 19 2014
Hospira Foundation Announces the Leukemia & Lymphoma Society as Winner of $100,000 (Mission: Care)2... Dec 19 2014
Hospira, Inc. -- Moody's raises Hospira's outlook to positive from negative Dec 18 2014
Danone says will keep Medical Nutrition business Dec 12 2014
Danone says keeping medical nutrition division Dec 12 2014
Danone says all divisions are key to its strategy Dec 12 2014
HOSPIRA INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Dec 11 2014
Merck-Cubist Deal Is On Despite Patent Setback Dec 09 2014
Hospira, Inc. Ticks Up On Favorable Patent Ruling vs. Cubist Pharmaceuticals Inc Dec 09 2014
Court rules Hospira can launch generic Cubicin in 2016 Dec 08 2014
Merck-Cubist deal about 'superbugs' Dec 08 2014
Today's Glance at the Market... Dec 02 2014
Hospira Foundation Announces 10 Recipients of (Mission: Care)2 Grants and Initiates Next Phase of... Dec 02 2014
Fresenius set to walk away from Danone unit - sources Nov 28 2014
Fresenius set to walk away from Danone unit-sources Nov 28 2014
HOSPIRA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and... Nov 20 2014
Hospira Mourns Passing of Founding Board Member Dr. Connie R. Curran Nov 17 2014
Hospira Mourns Passing of Founding Board Member Dr. Connie R. Curran Nov 17 2014
HOSPIRA INC Financials Nov 14 2014
10-Q for Hospira, Inc. Nov 09 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK